Erbitux Alternatives Compared
| Erbitux (cetuximab) | Keytruda (pembrolizumab) | Opdivo (nivolumab) |
|
|---|
| Erbitux (cetuximab) | Keytruda (pembrolizumab) | Opdivo (nivolumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Squamous Cell Carcinoma, Head and Neck Cancer, Colorectal Cancer. Erbitux may also be used for purposes not listed in this medication guide. |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, colorectal cancer, and lung cancer. Fatigue, skin... View more |
Related suggestions Colorectal Cancer
Head and Neck Cancer
|
|||||||||||||||||||||||
| More about Erbitux (cetuximab) | More about Keytruda (pembrolizumab) | More about Opdivo (nivolumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Erbitux has an average rating of 6.9 out of 10 from a total of 9 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 11% reported a negative effect. |
Keytruda has an average rating of 5.0 out of 10 from a total of 258 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 47% reported a negative effect. |
Opdivo has an average rating of 5.9 out of 10 from a total of 96 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 40% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Erbitux side effects |
View all Keytruda side effects |
View all Opdivo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Erbitux prices |
View all Keytruda prices |
View all Opdivo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
213 hours |
624 hours |
640.8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 23 drugs are known to interact with Erbitux:
|
A total of 595 drugs are known to interact with Keytruda:
|
A total of 595 drugs are known to interact with Opdivo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
February 12, 2004 |
N/A |
December 22, 2014 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Libtayo
Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Blenoxane
Blenoxane is used for hodgkin's lymphoma, non-hodgkin's lymphoma, squamous cell carcinoma ...
Unloxcyt
Unloxcyt (cosibelimab-ipdl) is an anti-PD-1 treatment for metastatic or advanced cutaneous squamous ...
Cemiplimab
Cemiplimab is used for basal cell carcinoma, non small cell lung cancer, squamous cell carcinoma
Bleomycin
Bleomycin is used for hodgkin's lymphoma, malignant pleural effusion, non-hodgkin's lymphoma ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.